TISSIUM’s De Novo FDA Authorization Signals Industry Shift
FDA De Novo nod for TISSIUM’s COAPTIUM CONNECT: a new era in sutureless nerve repair.
Read More
Author: Shajini
Revolution Medicines Secures Powerhouse $2B Funding in Groundbreaking Royalty Pharma Deal
Revolution inks $2B flexible deal with Royalty Pharma to fund RAS(ON) inhibitors in cancer.
Read More
Arialys Therapeutics Targets First in Class Precision Therapy for Autoimmune Encephalitis
ART5803 targets NMDA receptor autoantibodies, advancing precision therapy for autoimmune encephalitis.
Read More
Strategic Industry Context: Alzheimer’s Drug Reimbursement Faces Global Pressure
NICE deems donanemab and lecanemab not cost-effective, blocks NHS coverage for Alzheimer’s drugs.
Read MoreENHERTU Advances First-Line Endometrial Therapy in Phase 3 Trial
ENHERTU Phase 3 trial launches for first-line endometrial therapy targeting HER2-expressing tumors.
Read More